1. HBW Insight

Haleon’s US Eroxon Launch Falls Short Of Expectations

 
• By Tom Gallen

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

(Shutterstock)

Haleon’s launch of the first OTC topical erectile dysfunction treatment in the US has not hit the heights the company had hoped for.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Innovation & IP